

Borough Park
1428 36th Street
Suite 107
Brooklyn, NY 11218

Crown Heights
555 Lefferts Avenue
Brooklyn, NY 11225

Manhattan
57W 57Street
Suite 601
New York, NY 10019

Manhasset
333 East Shore Road
Suite 201
Manhasset, NY 11030

Rockville Centre
165 North Village Avenue
Suite 133
Rockville Center, NY 11750

Elmsford/Tarrytown
555 Taxter Road
3rd Floor
Elmsford, NY 10523

NYC Central Park West
115 Central Park West
Suite 15
New York, NY 10023

Woodbury
75 Froehlich Farm
Woodbury, NY 11797

Staten Island
27 New Dorp Lane
Staten Island, NY 10306



Office: 212-803-3339 Fax: 646-768-8600



Manhattan
225 E 70th Street
Suite 1E
New York, NY 10021

Queens
64-05 Yellowstone Blvd
CF104
Forest Hills, NY 11375

Manhattan
225 East 70th Street
New York, NY 10021

Holbrook/Ronkonkoma
233 Union Ave
Suite 207
Holbrook, NY 11741

Scarsdale
495 Central Park Avenue
Suite 205
Scarsdale, NY 10583

5 Towns
141 Washington Avenue
Cedarhurst, NY 11559

Long Beach
917 Beech Street
Long Beach, NY 11561

Riverhead
1228 E Main Street
Suite A
Riverhead, NY 11901

Bronx
226 West 238th Street
Bronx, NY 10463

COSENTYX

Provider Order Form

Date: _____

PATIENT INFORMATION

| | | |
|--|---------------------|--|
| Name: | DOB: | SEX: M <input type="checkbox"/> F <input type="checkbox"/> |
| ICD-10 code (required): | ICD-10 description: | |
| <input type="checkbox"/> NKDA Allergies: | Weight lbs/kg: | |

REFERRAL STATUS

New Referral Referral Renewal Medication/Order Change Benefits Verification Only Discontinuation Order

PHYSICIAN INFORMATION

| | |
|----------------------------|-----------------------------|
| Referral Coordinator Name: | Referral Coordinator Email: |
| Ordering Provider: | Provider NPI: |
| Referring Practice Name: | Phone: Fax: |
| Practice Address: | City: State: Zip Code: |

INDICATIONS AND USAGE

COSENTYX is a human interleukin-17A antagonist indicated for the treatment of:

- moderate to severe **plaque psoriasis (PsO)** in patients 6 years and older who are candidates for systemic therapy or phototherapy. (1.1)
- active **psoriatic arthritis (PsA)** in patients 2 years of age and older. (1.2)
- adults with **active ankylosing spondylitis (AS)**. (1.3)
- adults with active **non-radiographic axial spondyloarthritis (nr-axSpA)** with objective signs of inflammation. (1.4)
- active **enthesitis-related arthritis (ERA)** in pediatric patients 4 years of age and older. (1.5)
- adults with moderate to severe **hidradenitis suppurativa (HS)** (1.6)

DOSAGE AND ADMINISTRATION

Prior to COSENTYX initiation, complete all age-appropriate vaccinations, evaluate patients for tuberculosis (TB). (2.1). See Full Prescribing Information for instructions on preparation and administration of COSENTYX. (2.2, 2.9, 2.10)

- **Administration of Intravenous Formulation:** COSENTYX for intravenous use must be diluted prior to administration. Administer as an intravenous infusion after dilution over a period of 30 minutes. (2.10)

Plaque Psoriasis:

- **Subcutaneous Dosage in Adults:** Recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable. (2.3)
- **Subcutaneous Dosage in Pediatric Patients 6 Years and Older:** Recommended weight-based dosage is administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
 - For patients < 50 kg (at the time of dosing), the dose is 75 mg.
 - For patients ≥ 50 kg (at the time of dosing), the dose is 150 mg. (2.3)

Psoriatic Arthritis:

Adult Patients

Subcutaneous Dosage:

- For PsA patients with coexistent moderate to severe PsO, use the dosage and administration for PsO. (2.3)
- For other PsA patients, administer with or without a loading dosage.
 - **With a loading dosage:** 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
 - **Without a loading dosage:** 150 mg every 4 weeks
 - If a patient continues to have active PsA, consider a dosage of 300 mg every 4 weeks. (2.4)

Intravenous Dosage:

The recommended intravenous dosages are:

- **With a loading dosage:** 6 mg/kg given at Week 0 as a loading dose, followed by 1.75 mg/kg every 4 weeks thereafter (max. maintenance dose 300 mg per infusion).
- **Without a loading dosage:** 1.75 mg/kg every 4 weeks (max. maintenance dose 300 mg per infusion). (2.4)

Pediatric Patients 2 Years and Older

Subcutaneous Dosages: Administer by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter:

- For patients ≥ 15 kg and < 50 kg the dose is 75 mg.
- For patients ≥ 50 kg the dose is 150 mg. (2.5)

Ankylosing Spondylitis:

Subcutaneous Dosage:

Administer with or without a loading dosage.

The recommended dosages are:

- **With a loading dosage:** 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
- **Without a loading dosage:** 150 mg every 4 weeks.
- If a patient continues to have active ankylosing spondylitis, consider a dosage of 300 mg every 4 weeks. (2.6)

Intravenous Dosage:

The recommended intravenous dosages are:

- **With a loading dosage:** 6 mg/kg given at Week 0 as a loading dose, followed by 1.75 mg/kg every 4 weeks thereafter (max. maintenance dose 300 mg per infusion).
- **Without a loading dosage:** 1.75 mg/kg every 4 weeks (max. maintenance dose 300 mg per infusion). (2.6)

Non-Radiographic Axial Spondyloarthritis:

Subcutaneous Dosage:

Administer with or without a loading dosage. The recommended dosage is:

- **With a loading dosage:** 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
- **Without a loading dosage:** 150 mg every 4 weeks. (2.7)

Intravenous Dosage:

The recommended intravenous dosages are:

- **With a loading dosage:** 6 mg/kg given at Week 0 as a loading dose, followed by 1.75 mg/kg every 4 weeks thereafter (max. maintenance dose 300 mg per infusion).
- **Without a loading dosage:** 1.75 mg/kg every 4 weeks (max. maintenance dose 300 mg per infusion). (2.7)

- **Enthesitis-Related Arthritis:** Recommended weight-based dosage is administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.

- For patients ≥ 15 kg and < 50 kg the dose is 75 mg.
- For patients ≥ 50 kg the dose is 150 mg. (2.8)

- **Hidradenitis Suppurativa:** Recommended dosage is 300 mg administered by subcutaneous injection at Weeks 0, 1, 2, 3 and 4 and every 4 weeks thereafter. If a patient does not adequately respond, consider increasing the dosage to 300 mg every 2 weeks. (2.9)

Borough Park
1428 36th Street
Suite 107
Brooklyn, NY 11218

Crown Heights
555 Lefferts Avenue
Brooklyn, NY 11225

Manhattan
57W 57 Street
Suite 601
New York, NY 10019

Manhasset
333 East Shore Road
Suite 201
Manhasset, NY 11030

Rockville Centre
165 North Village Avenue
Suite 133
Rockville Center, NY 11570

Elmsford/Tarrytown
555 Taxter Road
3rd Floor
Elmsford, NY 10523

NYC Central Park West
115 Central Park West
Suite 15
New York, NY 10023

Woodbury
75 Froehlich Farm
Woodbury, NY 11797

Staten Island
27 New Dorp Lane
Staten Island, NY 10306



Manhattan
225 E 70th Street
Suite 1E
New York, NY 10021

Queens
64-05 Yellowstone Blvd
CF104
Forest Hills, NY 11375

Manhattan
225 East 70th Street
New York, NY 10021

Holbrook/Ronkonkoma
233 Union Ave
Suite 207
Holbrook, NY 11741

Scarsdale
495 Central Park Avenue
Suite 205
Scarsdale, NY 10583

5 Towns
141 Washington Avenue
Cedarhurst, NY 11559

Long Beach
917 Beech Street
Long Beach, NY 11561

Riverhead
1228 E Main Street
Suite A
Riverhead, NY 11901

Bronx
226 West 238th Street
Bronx, NY 10463

COSENTYX

Provider Order Form

DOSAGE FORMS AND STRENGTHS

Subcutaneous Injection

- Injection: 300 mg/2 mL solution in a single-dose UnoReady® pen and in a single-dose prefilled syringe. (3)
- Injection: 150 mg/mL solution in a single-dose Sensoready® pen and in a single-dose prefilled syringe. (3)
- Injection: 75 mg/0.5 mL solution in a single-dose prefilled syringe (for pediatric patients). (3)

Intravenous Infusion

- Injection: 125 mg/5 mL solution in a single-dose vial. (3)

CONTRAINDICATIONS

Serious hypersensitivity to secukinumab or any excipients in COSENTYX. (4)

WARNINGS AND PRECAUTIONS

- Infections: Serious infections have occurred. Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue COSENTYX until the infection resolves. (5.1)
- Hypersensitivity Reactions: If an anaphylactic reaction or other serious allergic reaction occurs, discontinue COSENTYX immediately and initiate appropriate therapy. (5.2)
- Tuberculosis (TB): Prior to initiating treatment with COSENTYX, evaluate for TB. (5.3)

- Inflammatory Bowel Disease (IBD): Cases of IBD were observed in clinical trials. Exercise caution when prescribing COSENTYX to patients with IBD. (5.4)
- Eczematous Eruptions: Cases of severe eczematous eruptions have occurred in patients receiving COSENTYX. (5.5)
- Immunizations: Avoid use of live vaccines in patients treated with COSENTYX. (5.7)

ADVERSE REACTION

Most common adverse reactions (> 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection. (6.1)